News
IDIBELL participates at the Researcher’s Night 2013 in Barcelona
On September 27 Biocomunica’t ‘ T (www.biocomunicat.com) organizes in Barcelona a new edition of the Researcher’s Night, a European science spreading project of the 7th Framework Programme of the European Union which will take place simultaneously in more than 300 European cities. The goal of the Reseachercher’s Night is to show the contribution of scientists […]
High levels of RANK protein interferes with the differentiation of mammary cells
Researchers of the Transformation and Metastasis research group at Bellvitge Biomedical Research Institute (IDIBELL), led by Eva González-Suárez, have shown that overexpression of RANK signalling pathway interferes with the differentiation of the cells that form the mammary glands. This produces an accumulation of undifferentiated cells that finally leads to tumor development. In previous studies, the […]
Discovered one of the mechanism that influences aggressiveness in Ewing’s Sarcoma
Caveolin-1 participates in the formation of new blood vessels around the tumor, facilitating growth and proliferation The finding opens the door to the investigation of new therapies against this childhood cancer Angiogenesis and solid tumors Future therapies Article’s reference EphA2-induced angiogenesis in Ewing sarcoma celles works through bGFG production and is dependent on caveolin-1.
Improvement in the diagnosis of testosterone deficiency syndrome in men allows an early treatment
The testosterone deficiency syndrome (TDS) is a clinical and biochemical syndrome associated with advancing age. It Is produced by a gradual drop in testosterone levels which affects the sexual sphere, leading to a decrease in sexual desire and morning erections, as well as decreasing the quality and frequency of erections. It can also affect the […]
IDIBELL’s researcher Eva González-Suárez awarded with a grant from Susan G. Komen® to investigate new therapies in breast cancer
The research group leader in transformation and metastasis of the Bellvitge Biomedical Research Institute (IDIBELL), Eva González-Suárez, has been awarded with a research grant from Susan G. Komen®, the world’s leading breast cancer organization. The project is funded with 450 000 dollars for the next three years. Komen was founded in 1982 with the goal […]
The epigenome differentiates the different human populations
What makes us different? What differentiates us from our neighbors, our friends or strangers from distant countries? For years we know that there are genetic differences among different human populations that contribute to their appearance and to a different susceptibility to disease. These small genetic differences between healthy individuals are called “polymorphisms”. The group of […]
Annual Report 2012
In 2012 the IDIBELL has positioned itself as a reference in healthcare innovation having driven a system of innovative public procurement in the field of health, in which the contractor and the bidder share the risks of the application of a new technology. The model, common in other countries, leverages the high purchasing capacity of […]
Patented a molecule that opens the door to develop new drugs against immune rejection
Researchers of the research group in Human Molecular Genetics of the Biomedical Research Institute of Bellvitge (IDIBELL), led by researcher Mercedes Pérez, have patented a peptide (a molecule consisting of a sequence of amino acids) that inhibits the immune response activated by the enzyme calcineurin which could serve to develop new more specific immunosuppressive drugs […]
Learning a language depends on good connection between regions of the left hemisphere of the brain
Language is a uniquely human ability. The average person’s vocabulary consists of about thirty thousand words, although there are individual differences in the ability to learn a new language. It has long been believed that language acquisition depends on the integration of the information between motor and auditory representation of words in the brain, but […]